RESET-SLE: Study to Evaluate the Safety and Efficacy of CABA-201 in People With Active Systemic Lupus Erythematosus

Basic Study Information

Purpose:
Systemic lupus erythematosus (SLE) is a disease where the immune system attacks healthy tissue. SLE can be unpredictable, flaring up and calming down over time. In some cases, it can damage organs like the kidneys, leading to a serious complication called lupus nephritis (LN). This can hurt your health and even be life-threatening. Unfortunately, there isn't a cure for lupus yet. Medications we have now can help manage the disease, but they often have side effects and sometimes aren't strong enough for severe cases. This is why scientists are actively researching new treatments for lupus, especially effective ones with fewer side effects, to help people with this challenging condition. This study will determine if a new drug, called CABA-201, will help SLE patient with lupus nephritis. You may be eligible to participate if you are 18-65 years old and have a clinical diagnosis of SLE.

Lead Researcher (Principal Investigator)

Lead Researcher:  Christopher Palma

Study Contact Information

Additional Study Details

Reimbursement:  Yes

Return to Search